Haemonetics
296 hedge funds and large institutions have $4.55B invested in Haemonetics in 2023 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 97 increasing their positions, 122 reducing their positions, and 34 closing their positions.
699% more call options, than puts
Call options by funds: $18M | Put options by funds: $2.25M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
6% more capital invested
Capital invested by funds: $4.3B → $4.55B (+$247M)
1% more funds holding
Funds holding: 294 → 296 (+2)
0.13% more ownership
Funds ownership: 99.9% → 100.03% (+0.13%)
20% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 122
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$75.6M |
| 2 |
Millennium Management
New York
|
+$26.4M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$13.5M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$10.6M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$9.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$38.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.1M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$20M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$15.1M |
| 5 |
Man Group
London,
United Kingdom
|
-$8.23M |
HAE Hedge Fund Activity: Q3 2023 in Review
296 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2023, worth a combined $4.55B — up 5.7% from $4.3B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new HAE positions and 34 closed out — a net gain of 4 holders — while 97 added to existing stakes and 122 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $75.6M. The largest seller was Arrowstreet Capital, cutting an estimated $38.9M.
- 296 institutional investors held Haemonetics (HAE) as of Q3 2023, up from 294 in Q2 2023.
- Funds reported $4.55B of Haemonetics stock for Q3 2023, up 5.7% quarter-over-quarter.
- 38 funds opened new Haemonetics positions in Q3 2023 and 34 closed out, a net change of +4 holders.
- The largest Haemonetics buyer in Q3 2023 was T. Rowe Price Investment Management, an estimated $75.6M added.
- The largest Haemonetics seller in Q3 2023 was Arrowstreet Capital, an estimated $38.9M sold.
Based on aggregated 13F filings for Q3 2023.